Cell & Gene: The Podcast

Listen On Apple Podcasts        Spotify        Google Podcast


BridgeBio's Approach To Gene Therapy & Nearing The Clinic With Dr. Eric David
BridgeBio's CEO of Gene Therapy, Dr. Eric David, explains the company's gene therapy programs for Canavan disease and congenital adrenal hyperplasia, their manufacturing plans, and the platform underpinning their approach to gene therapy.  Continue Reading..
  • Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease. 

  • Karen Kozarsky, Ph.D., Co-Founder and CSO of SwanBio explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord.

  • Bob Levis was diagnosed with Chronic Lymphocytic Leukemia in 2002 and was one of the early experimental trial participants at Penn Medicine for Dr. Carl June’s CAR-T therapy. Bob shares his remarkable journey with CLL as well as his important work with the CLL Society. 

  • Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector's advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility.

  • Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industry, and how Philadelphia earned the Cellicon Valley name for its continued innovation in cell and gene therapy, and more.

  • On this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hospital systems must evolve to meet the needs of cell and gene therapy patients as these complex therapies are commercialized. They discuss what comprises UPHS and the ongoing innovation it brings to advanced therapies as well as how the Health System stays patient-focused at all costs.

  • During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far they’ve come and the work that’s left to be done. And, they discuss what being patient-focused means in the world of rare diseases.


Erin Harris

Cell & Gene, the most valuable resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, brings you Cell & Gene: The Podcast. Join us as Cell & Gene Chief Editor, Erin Harris interviews industry and academic leaders on what they’re working on and how it's moving the sector forward. Each episode of Cell & Gene: The Podcast will explore approved and pipeline therapies, new trends in manufacturing, the long, regulated road to commercialization, and everything in between.